In-House Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-Small Cell Lung Cancer and Melanoma Patients

Tumor mutational burden (TMB) has emerged as an important potential biomarker for prediction of response to immune-checkpoint inhibitors (ICIs), notably in non-small cell lung cancer (NSCLC). However, its in-house assessment in routine clinical practice is currently challenging and validation is urg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Heeke, Simon, Benzaquen, Jonathan, Long-Mira, Elodie, Audelan, Benoit, Lespinet, Virginie, Bordone, Olivier, Lalvée, Salomé, Zahaf, Katia, Poudenx, Michel, Humbert, Olivier, Montaudié, Henri, Dugourd, Pierre-Michel, Chassang, Madleen, Passeron, Thierry, Delingette, Hervé, Marquette, Charles-Hugo, Hofman, Véronique, Stenzinger, Albrecht, Ilié, Marius, Hofman, Paul
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6769455/
https://ncbi.nlm.nih.gov/pubmed/31470674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11091271
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars